Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
Public ClinicalTrials.gov record NCT03346434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
Study identification
- NCT ID
- NCT03346434
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Months to 5 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2017
- Primary completion
- Jul 7, 2021
- Completion
- Jul 7, 2021
- Last update posted
- Jul 27, 2022
2017 – 2021
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Investigational Site | Birmingham | Alabama | 35209 | — |
| Regeneron Investigational Site | Gilbert | Arizona | 85234 | — |
| Regeneron Investigational Site | Long Beach | California | 90808 | — |
| Regeneron Investigational site | Los Angeles | California | 90027 | — |
| Regeneron Investigational Site | Palo Alto | California | 94304 | — |
| Regeneron Investigational Site | Rolling Hills Estates | California | 90274 | — |
| Regeneron Investigational Site | San Diego | California | 92123 | — |
| Regeneron Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Regeneron Investigational Site | Coral Gables | Florida | 33146 | — |
| Regeneron Investigational Site | Tampa | Florida | 33612-3807 | — |
| Regeneron Investigational Site | Columbus | Georgia | 31904 | — |
| Regeneron Investigational Site | Macon | Georgia | 31217 | — |
| Regeneron Investigational Site | Sandy Springs | Georgia | 39328 | — |
| Regeneron Investigational Site | Chicago | Illinois | 60611 | — |
| Regeneron Investigational Site | Rockville | Maryland | 20850 | — |
| Regeneron Investigational Site | Boston | Massachusetts | 02115 | — |
| Regeneron Investigational Site | Ann Arbor | Michigan | 48109-5314 | — |
| Regeneron Investigational Site | Ypsilanti | Michigan | 48197 | — |
| Regeneron Investigational Site | St Louis | Missouri | 63104-1003 | — |
| Regeneron Investigational Site | Lincoln | Nebraska | 68505 | — |
| Regeneron Investigational Site | Hackensack | New Jersey | 07601 | — |
| Regeneron Investigational Site | Forest Hills | New York | 113756 | — |
| Regeneron Investigational Site | New York | New York | 10032 | — |
| Regeneron Investigational Site | Rochester | New York | 14642 | — |
| Regeneron Investigational Site | Portland | Oregon | 97239 | — |
| Regeneron Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Regeneron Investigational Site | Charleston | South Carolina | 29425 | — |
| Regeneron Investigational Site | North Charleston | South Carolina | 29420 | — |
| Regeneron Investigational Site | Austin | Texas | 78723 | — |
| Regeneron Investigational Site | San Antonio | Texas | 78218 | — |
| Regeneron Investigational Site | Norfolk | Virginia | 23502 | — |
| Regeneron Investigational Site | Seattle | Washington | 98105 | — |
| Regeneron Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03346434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2022 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03346434 live on ClinicalTrials.gov.